Dr. Rudnick has extensive expertise in drug discovery and development and health care investments. He is retired from Canaan Partners, where he built the global venture capital firm’s capability in biopharmaceutical investing. Prior to joining Canaan Partners, Dr. Rudnick served as Chief Executive Officer and Chairman of CytoTherapeutics, a company developing stem cell-based therapies to combat chronic diseases. He also helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson that provides life-improving products to individuals with a focus on cancer and chronic illnesses. Dr. Rudnick received his M.D. from the University of Virginia. He also serves on the Board of Directors for G1 Therapeutics.